GALECTO INC (GLTO) Stock Price, Forecast & Analysis
USA - NASDAQ:GLTO - US36322Q2066 - Common Stock
GLTO Key Statistics, Chart & Performance
The current stock price of GLTO is 16.54 USD. In the past month the price decreased by -60.9%. In the past year, price decreased by -30.18%.
GLTO Latest News, Press Relases and Analysis
GLTO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.17 | 386.84B | ||
| AMGN | AMGEN INC | 14.8 | 174.30B | ||
| GILD | GILEAD SCIENCES INC | 14.42 | 146.55B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.2 | 107.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.58 | 69.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 874.81 | 58.48B | ||
| INSM | INSMED INC | N/A | 40.15B | ||
| NTRA | NATERA INC | N/A | 28.79B | ||
| BIIB | BIOGEN INC | 9.3 | 22.82B | ||
| INCY | INCYTE CORP | 16.44 | 20.61B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.28 | 20.63B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.95 | 14.90B |
Related stock screener links
About GLTO
Company Profile
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2020-10-29. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. The company is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Company Info
GALECTO INC
75 State Street, Suite 100
Boston MASSACHUSETTS DK-2200 US
CEO: Hans T. Schambye
Employees: 5
Phone: 14570705210
GALECTO INC / GLTO FAQ
What does GALECTO INC do?
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2020-10-29. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. The company is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
What is the current price of GLTO stock?
The current stock price of GLTO is 16.54 USD. The price increased by 234.14% in the last trading session.
Does GALECTO INC pay dividends?
GLTO does not pay a dividend.
What is the ChartMill rating of GALECTO INC stock?
GLTO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is GALECTO INC (GLTO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GLTO.
Can you provide the number of employees for GALECTO INC?
GALECTO INC (GLTO) currently has 5 employees.
What is the ownership structure of GALECTO INC (GLTO)?
You can find the ownership structure of GALECTO INC (GLTO) on the Ownership tab.
GLTO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GLTO. When comparing the yearly performance of all stocks, GLTO turns out to be only a medium performer in the overall market: it outperformed 69.29% of all stocks.
GLTO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLTO. While GLTO seems to be doing ok healthwise, there are quite some concerns on its profitability.
GLTO Financial Highlights
Over the last trailing twelve months GLTO reported a non-GAAP Earnings per Share(EPS) of -17.62. The EPS increased by 51.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -121.2% | ||
| ROE | -151.5% | ||
| Debt/Equity | 0 |
GLTO Forecast & Estimates
6 analysts have analysed GLTO and the average price target is 6.12 USD. This implies a price decrease of -63% is expected in the next year compared to the current price of 16.54.